Pharma major Lupin on Friday announced that it has received approval for its Propranolol Hydrochloride extended-release (ER) capsules in 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. The capsules will be used for the treatment of hypertension and prophylaxis of angina pectoris. Lupin is the first generic company to receive an approval of Pfizer Canada ULC’s Generic Inderal-LA capsules, the company said in a statement.The product will be manufactured from Lupin’s Pithampur unit-2 facility. As per IQVIA MAT December 2018 data, Propranolol Hydrochloride ER capsules had an annual sales of approximately CAD 8.6 million, the company said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!